Bitcoin price today: falls to 2-week low below $113k ahead of Fed Jackson Hole
In recent transactions reported to the Securities and Exchange Commission, Miles Patrick, CEO of Alphatec Holdings , Inc. (NASDAQ:ATEC), a medical device company with a market capitalization of $1.51 billion, sold shares of the company’s common stock valued at $135,032. According to InvestingPro data, the stock has experienced a significant 16.5% decline over the past week. The sale, executed on March 7, was part of a pre-established Rule 10b5-1 trading plan aimed at satisfying tax obligations linked to the vesting of restricted stock units. The shares were sold at a weighted average price of $10.64, with individual transaction prices ranging between $10.33 and $10.93. Despite recent price volatility, analysts maintain a positive outlook with price targets ranging from $11 to $22.50, as revealed in InvestingPro’s comprehensive analysis.
Additionally, on March 6, Patrick had 70,097 shares withheld by the issuer to cover tax withholding obligations, valued at $801,909, with each share priced at $11.44. Following these transactions, Patrick holds 5,857,603 shares directly and additional shares indirectly through personal investment vehicles. The company maintains strong liquidity with a current ratio of 2.73, while delivering impressive revenue growth of 26.8% over the last twelve months.
In other recent news, Alphatec Holdings reported its fourth-quarter 2024 earnings, revealing a revenue of $177 million, surpassing analyst expectations of $170.35 million. However, the company’s earnings per share (EPS) fell short, posting -$0.23 compared to the anticipated -$0.05. Despite the EPS miss, Alphatec achieved its first quarter of positive cash flow since its transformation, generating $9 million in free cash flow. The company has issued guidance for 2025, projecting a 20% revenue growth to $732 million.
Additionally, Alphatec announced a private offering of $300 million in convertible senior notes due 2030, with an option for purchasers to acquire an additional $50 million in notes. The company plans to use proceeds from this offering to fund capped call transactions and repurchase a portion of its outstanding notes due 2026. TD Cowen maintained its Buy rating for Alphatec, setting a price target of $22.50, citing the company’s robust market share expansion and positive cash flow outlook.
Furthermore, Alphatec entered into capped call transactions to mitigate potential stock dilution from the note conversions. These recent developments reflect the company’s strategic financial maneuvers and market positioning efforts.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.